Lymphatica Medtech is a technology company.
Lymphatica Medtech has raised $20.0M across 1 funding round.
Lymphatica Medtech has raised $20.0M in total across 1 funding round.
Lymphatica Medtech is a Swiss medical device company developing LymphoDrain, the first artificial lymphatic bypass implant for treating chronic lymphedema, a debilitating condition affecting over 10 million patients in the US and Europe, often post-cancer treatment.[2][5][7] The minimally invasive subcutaneous implant, activated by an external wearable controller and app, drains excess interstitial fluid from edematous limbs (initially arms post-breast cancer) to functional lymphatic areas, enabling personalized monitoring and treatment while under clinical investigation in the LymphoPilot first-in-human study at Lausanne University Hospital (CHUV).[1][2][4] With FDA Breakthrough Device Designation accelerating its path to market and a €17.9M Series B funding round closed recently, the company shows strong growth momentum toward addressing an unmet need in lymphatic disease management.[3][4][5]
Lymphatica Medtech SA was founded in July 2017 as a spin-off from the Swiss Federal Institute of Technology Lausanne (EPFL) and CHUV, leveraging academic research into lymphatic diseases.[4][5][8] Co-founders Marco Pisano (CEO) and Valentina Triacca (COO), both with expertise in biomedical engineering and lymphatic research, identified the need for active lymphatic drainage solutions after observing limitations in conservative treatments like compression therapy.[3][4][5] Early traction came from the LymphoPilot clinical study, a successful first-in-human trial at CHUV led by Prof. Lucia Mazzolai, demonstrating feasibility, safety, and preliminary efficacy, which paved the way for FDA Breakthrough Designation and Series B funding from investors like HTGF, Panakès, and TechWald.[2][4][5]
Lymphatica rides the wave of precision medtech for lymphatic and vascular diseases, targeting a $5B+ global lymphedema market underserved by symptomatic treatments amid rising cancer survivorship (e.g., post-mastectomy cases).[5][7] Timing aligns with advances in implantable microdevices, AI-driven personalization, and regulatory fast-tracks like FDA Breakthrough, fueled by post-pandemic emphasis on chronic disease innovation and aging populations.[3][4] As an EPFL/CHUV spin-off, it exemplifies Switzerland's medtech ecosystem strength, influencing broader adoption of active implants in cardiovascular and oncology-adjacent fields while partnering with hospitals for scalable clinical translation.[5][8]
Lymphatica is poised for pivotal trials, FDA approval, and US/EU commercialization post-Series B, potentially capturing first-mover advantage in lymphedema by 2027-2028 with expanded indications (e.g., legs).[4][5] Trends like wearable-integrated implants and value-based care will amplify its impact, evolving it from startup to lymphatic disease leader and inspiring similar therapies for underserved vascular conditions. This positions Lymphatica to transform millions of lives, fulfilling its mission to empower doctors and patients against lymphatic burdens.[1][3]
Lymphatica Medtech has raised $20.0M in total across 1 funding round.
Lymphatica Medtech's investors include Soffinova Partners.
Lymphatica Medtech has raised $20.0M across 1 funding round. Most recently, it raised $20.0M Series B in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $20.0M Series B | Soffinova Partners |